Using the f2 Factor to Improve Bioequivalence Studies for Pazopanib
Author Information
Author(s): Henriques Sara Carolina, Leblanc Ana, Simões Sérgio, Fonseca Marlene, Pimentel Francisco Luís, Almeida Luis, Silva Nuno Elvas
Primary Institution: BlueClinical Ltd.
Hypothesis
Can the f2 factor provide a more reliable assessment of bioequivalence in pilot studies of pazopanib?
Conclusion
The f2 factor shows promise in reducing uncertainty in pilot studies and aids in decisions to proceed with pivotal bioequivalence studies.
Supporting Evidence
- The f2 factor was calculated to assess the similarity of drug absorption rates.
- Pilot studies showed high variability, but the f2 factor indicated potential bioequivalence.
- Results from pilot studies were confirmed in larger pivotal studies.
Takeaway
Researchers tested a new method to check if two versions of a medicine are the same, and it worked well even with a small number of people.
Methodology
The study applied the f2 factor to pharmacokinetic data from pilot bioequivalence trials of pazopanib.
Potential Biases
The small sample size may introduce variability and uncertainty in the results.
Limitations
The study was limited to drugs following a one compartment model and based on simulated concentration-time profiles.
Participant Demographics
{"male":6,"female":17,"age_range":"22-42"}
Statistical Information
P-Value
p<0.05
Confidence Interval
[80.00–125.00]%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website